Literature DB >> 7753064

Functional decline in Huntington's disease.

A Feigin1, K Kieburtz, K Bordwell, P Como, K Steinberg, J Sotack, C Zimmerman, C Hickey, C Orme, I Shoulson.   

Abstract

We prospectively evaluated 129 patients with manifest Huntington's disease (HD) to determine the rate of illness progression and the clinical features that correlate with functional decline. A single examiner evaluated each patient using the HD Functional Capacity Scale. Standardized motor performance was also assessed in 94 of the patients (73%) using the HD Rating Scale. Total Functional Capacity declined at a rate of 0.63 +/- 0.75 U per year. As functional capacity worsened, chorea lessened, and dystonia intensified. There was no correlation between rate of functional decline and age at onset of HD, body weight, gender of affected parent, or history of neuroleptic use.

Entities:  

Mesh:

Year:  1995        PMID: 7753064     DOI: 10.1002/mds.870100213

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  19 in total

1.  Clozapine versus placebo in Huntington's disease: a double blind randomised comparative study.

Authors:  J P van Vugt; S Siesling; M Vergeer; E A van der Velde; R A Roos
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-07       Impact factor: 10.154

Review 2.  Using advances in neuroimaging to detect, understand, and monitor disease progression in Huntington's disease.

Authors:  H D Rosas; A S Feigin; Steven M Hersch
Journal:  NeuroRx       Date:  2004-04

3.  Motor abnormalities in premanifest persons with Huntington's disease: the PREDICT-HD study.

Authors:  Kevin M Biglan; Christopher A Ross; Douglas R Langbehn; Elizabeth H Aylward; Julie C Stout; Sarah Queller; Noelle E Carlozzi; Kevin Duff; Leigh J Beglinger; Jane S Paulsen
Journal:  Mov Disord       Date:  2009-09-15       Impact factor: 10.338

4.  Differences in duration of Huntington's disease based on age at onset.

Authors:  T Foroud; J Gray; J Ivashina; P M Conneally
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-01       Impact factor: 10.154

5.  Safety of Converting From Tetrabenazine to Deutetrabenazine for the Treatment of Chorea.

Authors:  Samuel Frank; David Stamler; Elise Kayson; Daniel O Claassen; Amy Colcher; Charles Davis; Andrew Duker; Shirley Eberly; Lawrence Elmer; Erin Furr-Stimming; Mark Gudesblatt; Christine Hunter; Joseph Jankovic; Sandra K Kostyk; Rajeev Kumar; Clement Loy; William Mallonee; David Oakes; Burton L Scott; Victor Sung; Jody Goldstein; Christina Vaughan; Claudia M Testa
Journal:  JAMA Neurol       Date:  2017-08-01       Impact factor: 18.302

6.  Unraveling a role for dopamine in Huntington's disease: the dual role of reactive oxygen species and D2 receptor stimulation.

Authors:  Delphine Charvin; Peter Vanhoutte; Christiane Pagès; Emilliana Borrelli; Emiliana Borelli; Jocelyne Caboche
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-15       Impact factor: 11.205

7.  Striatal hypometabolism in premanifest and manifest Huntington's disease patients.

Authors:  Diego Alfonso López-Mora; Valle Camacho; Jesús Pérez-Pérez; Saül Martínez-Horta; Alejandro Fernández; Frederic Sampedro; Alberto Montes; Gloria Andrea Lozano-Martínez; Beatriz Gómez-Anson; Jaime Kulisevsky; Ignasi Carrió
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-06-28       Impact factor: 9.236

8.  Thalamic metabolism and symptom onset in preclinical Huntington's disease.

Authors:  A Feigin; C Tang; Y Ma; P Mattis; D Zgaljardic; M Guttman; J S Paulsen; V Dhawan; D Eidelberg
Journal:  Brain       Date:  2007-09-24       Impact factor: 13.501

Review 9.  Symptomatic treatment of Huntington disease.

Authors:  Octavian R Adam; Joseph Jankovic
Journal:  Neurotherapeutics       Date:  2008-04       Impact factor: 7.620

10.  How different aspects of motor dysfunction influence day-to-day function in huntington's disease.

Authors:  Noelle E Carlozzi; Stephen G Schilling; Nicholas R Boileau; Kelvin L Chou; Joel S Perlmutter; Samuel Frank; Michael K McCormack; Julie C Stout; Jane S Paulsen; Jin-Shei Lai; Praveen Dayalu
Journal:  Mov Disord       Date:  2019-10-14       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.